MARKET

GYRE

GYRE

Gyre Therapeutics Inc
NASDAQ
10.39
-1.11
-9.65%
After Hours: 10.39 0 0.00% 16:20 05/14 EDT
OPEN
11.50
PREV CLOSE
11.50
HIGH
11.56
LOW
10.33
VOLUME
92.53K
TURNOVER
--
52 WEEK HIGH
19.00
52 WEEK LOW
6.11
MARKET CAP
974.14M
P/E (TTM)
87.98
1D
5D
1M
3M
1Y
5Y
1D
Noble Financial Keeps Their Buy Rating on Gyre Therapeutics (GYRE)
TipRanks · 1d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 2d ago
Weekly Report: what happened at GYRE last week (0505-0509)?
Weekly Report · 2d ago
Gyre Therapeutics GAAP EPS of $0.00 misses by $0.03, revenue of $22.1M misses by $6.3M
Seeking Alpha · 5d ago
Gyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 5d ago
Gyre Therapeutics Q1 Sales $22.06M Miss $28.70M Estimate
Benzinga · 5d ago
Gyre Therapeutics Q1 Sales $22.06M Down From $27.17M YoY
Benzinga · 5d ago
*Gyre Therapeutics Backs 2025 Rev $118M-$128M >GYRE
Dow Jones · 5d ago
More
About GYRE
More
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
Recently
Symbol
Price
%Change

Webull offers Gyre Therapeutics Inc stock information, including NASDAQ: GYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GYRE stock methods without spending real money on the virtual paper trading platform.